Thursday, 29 May 2014
Limerick, Ireland - May 29, 2014 One-year follow-up data from 907 Japanese patients who received the Zilver PTX drug-eluting stent showed positive results in keeping open the superficial femoral artery (SFA). The postmarket surveillance (PMS) study, designed to evaluate the stents performance in real-world patient use, was presented at the 2014 Euro PCR meeting.
The PMS study was based in Japan and presented by Hiroyoshi Yokoi, M.D. of Fukuoka Sanno Hospital. It included 907 patients with peripheral arterial disease (PAD) treated with Zilver PTX. Of those, 838 were eligible for 12-month follow up. After one year, 91.4 percent of the patients in the follow-up group did not need target lesion revascularization (TLR) of the SFA. The 84.8 percent primary patency result in the PMS study is similar to results from earlier Zilver PTX studies .
Were very pleased with the data from the Japan PMS study because the study included a broad range of lesion types and lengths similar to what doctors treat on a daily basis. Like our other studies, this evaluation shows that for most patients there is an enduring drug effect from Zilver PTX a year after implantation, said Mark Breedlove, global leader for Cook Medicals Peripheral Interventional (PI) division.
Zilver PTX has been approved for use in the European Union since August 2009 and the United States and Japan since 2012. Since its release, the stent has been used to treat more than 25,000 patients in North America, Europe, Asia, South America, Australia and New Zealand.
About Cook Medical
Since 1963 Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world's healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at www.cookmedical.com, and for the latest news, follow us on Twitter and LinkedIn.